Opendata, web and dolomites

BoVLP-BVD

Development of Tagged (DIVA), Virus-Like-Particle polyantigenic Vaccine against Bovine Viral Diarrhea virus (BVDc)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BoVLP-BVD project word cloud

Explore the words cloud of the BoVLP-BVD project. It provides you a very rough idea of what is the project "BoVLP-BVD" about.

countries    infection    agro    tagged    vaccinated    experimental    fulfil    systematically    viral    business    decide    modified    profile    cattle    differentiate    killed    90    systematic    agent    bvd    eradication    formulation    euros    environmental    incidence    confirm    vaccine    particle    diarrhea    productivity    basic    animal    social    start    antibiotics    had    antigenic    approximately    of    virus    market    prospective    recombinant    persistent    fight    worldwide    mandatory    oacute    million    lifetime    precisely    herd    becomes    poly    herds    reproduction    hundreds    infectious    context    vaccines    exploring    infected    programs    confirming    50    intends    reduce    regulatory    food    animals    disease    patented    economic    suboptimal    calendar    industry    prior    hut    plan    aquil    bovine    vaccination    manufacturing    endemic    public    pressure    livestock    prevent    feasibility    point    wishes    commercial    investing    bodies    exposed    tool    live    diseases    bvdv   

Project "BoVLP-BVD" data sheet

The following table provides information about the project.

Coordinator
AQUILON CYL SOCIEDAD LIMITADA 

Organization address
address: LUGAR FACULTAD DE VETERINARIA S/N CAMPUS VEGAZANA
city: LEON
postcode: 24000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.aquiloncyl.com/proyectos-i-d/vacuna-contra-la-diarrea-virica-bovina
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.2.4. (Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy)
2. H2020-EU.3.2.1. (Sustainable agriculture and forestry)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.2.2. (Sustainable and competitive agri-food sector for a safe and healthy diet)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2017-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AQUILON CYL SOCIEDAD LIMITADA ES (LEON) coordinator 50˙000.00

Map

 Project objective

In a general context of environmental, social and legal pressure to reduce the use of antibiotics to fight diseases in livestock animals, cost-effective vaccination becomes the focus of most of the industry, regulatory and agro-food public bodies. Development of new vaccines to prevent the disease and therefore avoid the use of antibiotics or to improve suboptimal available vaccines is now an European and industry priority. Bovine viral diarrhea virus (BVDV) is an important infectious agent of cattle worldwide that affects herd productivity and reproduction. BVD has been and is an endemic disease in all countries where no systematic eradication and control programs have been established. Under these conditions, approximately 50% of the herds have or have had animals with persistent infection, and approximately 90% of the cattle have been exposed to the virus at some point during their lifetime.Infection with BVDV has a major economic impact, estimated in hundreds of euros per animal for a European hut of around 80 million animals. Modified, live and killed vaccines have been available for more than 50 years, yet the incidence of BVDV-induced disease remains significant, confirming a need for improved vaccines. Aquilón intends to develop a new recombinant vaccine against BVDV using a Virus-Like- Particle patented technology. The vaccine will be poly-antigenic, non-live, tagged so that can differentiate vaccinated from infected animals, and cost-effective from the manufacturing side. Prior to start the experimental phase of the project, Aquilón wishes to confirm its commercial feasibility, defining precisely the Target Product Profile and exploring systematically its market potential and prospective cost/calendar of development to fulfil regulatory requirements. These studies are mandatory for the formulation of a business plan which will be the basic tool to decide investing in the future development of the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BOVLP-BVD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BOVLP-BVD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.2.4.;H2020-EU.3.2.1.;H2020-EU.2.3.1.;H2020-EU.3.2.2.)

ARMeD_free (2017)

Antibiotic resistance-free meat and dairy products

Read More  

KEEP-IT-UP (2018)

KEEP-IT-UP: Redefining shelf life monitoring in the global food industry with a new intelligent Time-Temperature Indicator for perishable products

Read More  

geoBone (2018)

geoBone: A Unique Mineral Supplement for Bone Health and Prevention of Osteoporosis SustainablyProduced from Geothermal Resources through a Ground-breaking Process.

Read More